Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02898259
Title Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

B-cell lymphoma

Therapies

Ixazomib + Lenalidomide + Rituximab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.